

# New Horizons in Pustular Psoriasis

## Will You be Ready?

Pustular psoriasis may be rare, but it is associated with high rates of morbidity, mortality, and recurrence, and it can be difficult to treat.

Clinicians, it's time to **get ready** to translate the rapidly evolving guidance and emerging science to improve outcomes for our pustular psoriasis patients. Join your colleagues, and expert faculty Dr. Mark Lebwohl in these upcoming virtual, small-group, *CME Meet-Ups* to discuss:

◊ Lack of U.S guidance that complicates diagnosis and disease

◊ Recent pathophysiologic findings for pustular psoriasis and implications for treatment

◊ Latest safety and efficacy data for new and emerging agents



### Mark Lebwohl, MD

Dean for Clinical Therapeutics  
Chairman Emeritus  
Kimberly and Eric J. Waldman  
Department of Dermatology  
Icahn School of Medicine at Mount Sinai  
New York, NY

Find a Time that Works for You

[www.ACHLcme.org/  
pustularpsoriasisCMEwebinars](http://www.ACHLcme.org/pustularpsoriasisCMEwebinars)

Sponsored by

**ACHL**  
ACADEMY for  
CONTINUED HEALTHCARE LEARNING

Sponsored by the Academy for Continued Healthcare Learning.  
This activity is supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.